Results 111 to 120 of about 6,652 (162)
Effects of cilostazol for in-stent restenosis after carotid artery stenting: a meta-analysis. [PDF]
J Cardiothorac SurgSun J +6 more
europepmc +1 more source
Hemorrhage Risk Associated with Anticoagulant and Antiplatelet Drug Combinations: Insights from the USFDA Adverse Event Reporting System. [PDF]
J Clin MedSridharan K, Sivaramakrishnan G.
europepmc +1 more source
T-World Virtual Human Cardiomyocyte. II. Organ-Scale Simulations and Applications. [PDF]
Circ ResTomek J +12 more
europepmc +1 more source
Prognostic factors in aneurysmal subarachnoid hemorrhage during the clazosentan era: a multicenter study using multivariate analyses and machine learning model. [PDF]
Neurosurg RevMuraoka S +12 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs & Aging, 1999
Cilostazol is an antiplatelet agent with vasodilating properties that has been used in the treatment of patients with peripheral ischaemia such as intermittent claudication. The drug inhibits platelet aggregation induced by ADP, collagen and arachidonic acid.
E M, Sorkin, A, Markham
+6 more sources
Cilostazol is an antiplatelet agent with vasodilating properties that has been used in the treatment of patients with peripheral ischaemia such as intermittent claudication. The drug inhibits platelet aggregation induced by ADP, collagen and arachidonic acid.
E M, Sorkin, A, Markham
+6 more sources
The pharmacology of cilostazol
Diabetes, Obesity and Metabolism, 2002Cilostazol (6‐[4‐(1‐cyclohexyl‐ 1H ‐tetrazol‐5‐yl)butoxy]‐3,4‐dihydro‐2(1 H )‐quinolinone; OPC‐13013) is a 2‐oxo‐quinoline derivative with antithrombotic, vasodilator, antimitogenic and cardiotonic properties.
exaly +3 more sources
Heart disease (Hagerstown, Md.), 2002
Cilostazol is a phosphodiesterase III inhibitor that has been shown to be effective for treatment of symptomatic intermittent claudication. It is generally well tolerated, but is contraindicated in patients with severe heart failure because of the potential detrimental effects demonstrated by other agents in the same class.
+7 more sources
Cilostazol is a phosphodiesterase III inhibitor that has been shown to be effective for treatment of symptomatic intermittent claudication. It is generally well tolerated, but is contraindicated in patients with severe heart failure because of the potential detrimental effects demonstrated by other agents in the same class.
+7 more sources